FindTrial
Sign In

0.3 mL IM) at day 180

2 trials

Sponsors

National Vaccine Institute

Conditions

Prevention of COVID-19 with SARS CoV-2 mRNA vaccine platform, comparing standard dose and low dose, in healthy Thai adolescent SARS-CoV-2, mRNA vaccine, COVID-19 vaccine, Adolescent, Immunogenicity, ReactogenicityPrevention of COVID-19 with heterologous prime-boost SARS-CoV-2 vaccine with inactivated and mRNA vaccine platforms, comparing standard dose vs low dose and 3-week vs 6-week interval, in healthy Thai adolescent. SARS-CoV-2, mRNA vaccine, Inactivated SARS-CoV-2 vaccine, COVID-19 vaccine, Adolescent, Immunogenicity, Reactogenicity

Phase 2

Safety and Immunogenicity of SARS CoV-2 mRNA vaccine platform in healthy Thai adolescent (COVID-19)
Active, not recruitingTCTR20210917004
National Vaccine InstitutePrevention of COVID-19 with SARS CoV-2 mRNA vaccine platform, comparing standard dose and low dose, in healthy Thai adolescent SARS-CoV-2, mRNA vaccine, COVID-19 vaccine, Adolescent, Immunogenicity, Reactogenicity
Start: 2021-09-18Target: 120Updated: 2026-08-03
Safety and Immunogenicity of heterologous prime-boost SARS-CoV-2 vaccine with inactivated and mRNA vaccine platforms in healthy Thai adolescent
Active, not recruitingTCTR20210923012
National Vaccine InstitutePrevention of COVID-19 with heterologous prime-boost SARS-CoV-2 vaccine with inactivated and mRNA vaccine platforms, comparing standard dose vs low dose and 3-week vs 6-week interval, in healthy Thai adolescent. SARS-CoV-2, mRNA vaccine, Inactivated SARS-CoV-2 vaccine, COVID-19 vaccine, Adolescent, Immunogenicity, Reactogenicity
Start: 2021-10-17Target: 80Updated: 2026-08-03

Related Papers

Heterologous Prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among Healthy Thai Adolescents
Vaccine X2022-08-297 citations